Upregulation of lnc-ZNF281 Inhibits the Progression of Glioma via the AKT/GSK-3 < em > β < /em > / < em > β < /em > -Catenin Signaling Pathway

J Immunol Res. 2021 May 11;2021:5573071. doi: 10.1155/2021/5573071. eCollection 2021.ABSTRACTThe purpose of this study is to elucidate the roles and potential underlying mechanisms of long noncoding RNA lnc-ZNF281 in glioma. We performed qRT-PCR to detect the expression levels of lnc-ZNF281 in glioma tissues. The effects of lnc-ZNF281 on the proliferative and migrative abilities of T98G and HS683 glioma cells were examined by cell proliferation assay, colony formation assay, wound-healing assay, and transwell assay. Also, the effects of lnc-ZNF281 on AKT/GSK-3β/β-catenin pathway were analyzed. The results showed that the expression of lnc-ZNF281 in glioma tissues was decreased compared with normal tissues. lnc-ZNF281 overexpression inhibited the proliferative and migrative abilities of glioma cells, while lnc-ZNF281 knockdown obtained the opposite findings. Besides, overexpression of lnc-ZNF281 in glioma cells inactivated the AKT/GSK-3β/β-catenin signaling pathway. Furthermore, β-catenin activation reversed the suppressive effects of lnc-ZNF281 on glioma cells. Taken together, lnc-ZNF281 inhibits glioma cell proliferation and migration via AKT/GSK-3β/β-catenin pathway and may serve as a potential target for glioma treatment.PMID:34056009 | PMC:PMC8131163 | DOI:10.1155/2021/5573071
Source: Journal of Immunology Research - Category: Allergy & Immunology Authors: Source Type: research